Immunosuppressants | sciencenewsnet.in

Breaking News

These jacks-of-all-trades are masters, too: Yeast study helps answer age-old biology question

Living with Stage 3 lung cancer in your 80s and 90s

ETRI published Key International Standards for Wearable Healthcare

Study Unveils Balance of AI and Preserving Humanity in Health Care

Press Registration for the ASRS 2024 Annual Scientific Meeting Now Open

A systematic review of three key sugar metabolism proteins, HXK, SnRK1 and TOR, in the regulatory network of plant growth, development and stress

Orchid Welcomes Distinguished Clinical and Genetics Leaders to its Advisory Boards

Potential new worlds rescued by citizens of Earth! Early results of people-powered astronomy project ‘out of this world’

Genetic variations may predispose people to Parkinson’s disease following long-term pesticide exposure, study finds

BIMM University chooses Figshare to showcase its non-traditional research and creative practitioner outputs

26 Apr, 2024

COVID-19 vaccine elicits weak antibody response in people taking immunosuppressant

November 19, 2021 sarah JonasResearch Results

People taking TNF inhibitors, a kind of immunosuppressive drug used to treat rheumatoid arthritis and other autoimmune conditions, produced a weaker and shorter-lived antibody response after two doses of Pfizer’s COVID-19 vaccine, according to a study from Washington University School of Medicine in St. Louis. A third vaccine dose drove antibody levels back up, indicating that this additional dose may provide protection as the virus’s delta variant continues to spread.